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Western blotting studies of IgG antibodies, IgG avidity and
IgG subclasses during the follow up of patients with pul-
monary tuberculosis, under treatment
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Background: WHO in 2007, estimated that the incidence
of tuberculosis in worldwide was about 8.8 million new cases
per year. In attention to WHO recommendations serological
tests are currently being studied and standardized for the
diagnosis of the active and latent disease.
Methods: From clinical strain of Mycobacterium tuber-
culosis, maintained in our laboratory, the antigen was
prepared and after SDS PAGE, the proteins were transferred
to nitrocellulose membrane for Western Blotting analysis.
For IgG antibodies detections we used monoclonal antibod-
ies anti IgG labeled with peroxidase diluted 1/500, and for
IgG subclasses we used anti-IgG1 and anti-IgG3 labeled with
biotin diluted 1/100 and streptavidin-peroxidase diluted
1/100. The reactions were revealed with a solution of 4
chloro-alpha-naphtol. For IgG avidity, after the ﬁrst incu-
bation with serum samples, the strips were washed with 8M
urea for 5 minutes.
Results: We tested serum samples from 5 patients, taken
at the beginning and the end of treatment, after 6 months.
The region of 30 kDa, related with metabolic activity of
mycobacteriae, has been recognized in all samples for IgG
antibodies, with intensity stronger in the last sample. There
was the appearance of band in the region of 16 kDa in the
ﬁrst and in the last samples of two patients. In the others
three patients this band appears only in the last sample,
but after washing with urea less intensity of this band was
observed. The region of 16 KDa is expressed by M. tubercu-
losis when it is maintained with low oxygen tension and it
is associated with latent infection. The region of 6 kDa is
better recognized in the last samples, and this region is not
sensitive to urea treatment. With regard to IgG1, antibod-
ies were most frequent in the region of 38 kDa, considered
as speciﬁc protein of the M. tuberculosis; IgG3 antibody
appears in serum samples from four patients reacting with
bands in the regions of 30 kDa, 20 kDa and 6 kDa, at random.Conclusion: The physiological pathological roles of anti-
bodies reacting with the bands studied are being evaluated
with a larger number of patients.
doi:10.1016/j.ijid.2010.02.433
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multiplex real-time PCR method for presumptive identi-
cation of NAP1 clone of Clostridium difﬁcile from stools
. Jayaratne1,∗, C. Lee1, C. Rutherford2
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Background: Clostridium difﬁcile infection (CDI) is the
eading cause of nosocomial diarrhea in adults and paedi-
tric patients. There has been signiﬁcant morbidiity and
ortality related to CDI due to the presence of hyperviru-
ent strain (NAP1) associated with unregulated production of
oxin. NAP1 has been responsible for a number of outbreaks
n many countries. Rapid detection for the presence of NAP1
s essential for appropriate patient management and to min-
mize nosocomial transmission. Currently, pulsed-ﬁeld gel
lectrophoresis (PFGE) and repetitive sequence-based (REP-
CR) methods which require bacterial culture have been
sed to identify NAP1. A 18 bp deletion in the tcdC gene
nd the presence of cdtA gene (binary toxin) have been
hown to be associated with NAP1. We describe a rapid mul-
iplex real-time PCR method for presumptive identiﬁcation
f NAP1.
Methods: Ninety blinded frozen stool samples previously
ested for toxin A/B by CD TOX A/B® II EIA (TechLab, Inver-
ess Medical) were used. A fragment of tcdC ﬂanking the
8 bp deletion (surrogate marker for tcdA/tcdB), cdtA, and
6S rDNA (internal control) genes were ampliﬁed using Mul-
iplex QuantiTechTM (Qiagen, Inc.) and detected by TaqMan
robes. ProGastroTM (Prodesse, Inc.) kit that detects tcdB
as used for comparison. DNA from stools were extracted
sing easyMAG (BioMerieux Inc) and tested accodring to
anufacturers’ speciﬁcations. Five !l of the same DNA was
sed for the in-house method. Both real-time PCR ampli-
cations were done in a Rotor-Gene 6000 (Corbette, Inc.).
CR products from both tcdC and cdtA positive samples were
eparated on agarose gels to detect tcdC deletion.
Results: DNA from 85 specimens were positive for tcdC
toxigenic) and 53 of those showed the presence of cdtA
ene (presumptive NAP1). DNA from none of the specimens
ere positive for cdtA only.The tcdB detection by ProGas-
roCDTM was concordant with the detection of tcdC. Gel
lectrophoresis of all tcdC and cdtA positive PCR products
etected the 18 bp deletion in the tcdC amplicon and were
onﬁrmed as NAP1 by PFGE. All cdtA negative DNA samples
ere negative for 18 bp deletion in the tcdC.
Conclusion: Detection of toxigenic strains by the in-house
ethod is comparable to the commercial assay and it pre-
umptively identiﬁed the presence of NAP1.
oi:10.1016/j.ijid.2010.02.434
